Life Sciences Archive » July, 2013

Life Sciences - July, 2013

274 articles

• J&J, OraPharma Seek Court's OK On Arbitration Award
• 3 Pitfalls To Avoid As ACA Sunshine Act Takes Effect
• Cyberonics Settles $200M Suit Over Therapy System Patents
• FDA Diabetes Drug Inquiry Finds No Cancer Risks
• Dems Move To Toughen Supplement Labeling Requirements
• Patent Holders Should Bear Burden Of Proof, High Court Told
• Congress Must Clarify FDA Oversight On Compounding: GAO
• ITC To Review ClearCorrect Infringement Ruling
• Suit Over Mumps Vaccine Shows No False Claims, Merck Says
• A Post-Actavis Approach To Reverse Payment Settlements
• Deals Rumor Mill: KKR, Accenture, Soros
• AstraZeneca Inks $815M Deal To Develop Anemia Drug
• KKR To Buy Another Clinical Research Co., Plans Merger
• SAC Class Plaintiffs Urge Approval Of $600M SEC Settlement
• Shareholders Sue To Block $8.5B Actavis, Warner Chilcott Deal
• Appeals Court OKs $2.7M Royalty Verdict Against Biomet Units
• Roche Loses Bid To Appeal Accutane Judge's Recusal Ruling
• Cubist Inks Deal To Buy Trius, Optimer For Up To $1.6B
• Judge Won't Toss $100M Trade Secret Suit Against Akorn
• Patients Get FDA's Ear, Opening Door To Relaxed Approvals
• FDA Details Mandatory Drug Warning Label Updates
• Wyeth Paying $491M To End Criminal, Civil Rapamune Cases
• Supplement Maker Pushes To Keep $4M Malpractice Suit Alive
• Deals Rumor Mill: Roche, Invensys, Rio Tinto
• CORRECTED: State Law Claims In Philly Reglan Suits Survive Mensing
• An Insider's View Of 11th Circ. Patent Dispute Forum Case
• PE-Backed Kinetic Drops $485M On UK Wound Care Biz
• Herbalife Urges Judge To Toss 'Pyramid Scheme' Class Action
• Essilor Pays $2B For PPG's Stake In Polarized Lens Maker
• Eli Lilly Dodges More Claims In Darvocet, Darvon MDL
• Accentia Faces Investor Suit Over Lymphoma Vaccine
• Telegraph Hill Closes Health Care VC Fund At $310M
• Teva MS Drug Patent Backed By UK High Court In Mylan Row
• Husch Blackwell Snags IP Partner From Troutman Sanders
• SEC's New Focus On Accounting Fraud: What's On Its Radar?
• LA Atty Sues DePuy Over Allegedly Faulty Hip Implant
• Pfizer Splits Into 3 Segments In Latest Shakeup
• The Noneffect Of Myriad On Personalized Medicine
• Perrigo Puts Up $8.6B For Elan
• China Bribery Crackdown May Trigger US, UK Investigations
• A-Rod's Cousin Tries To Duck Deposition In Drug Clinic Case
• Alcon Sues To Block Mylan's Bid For Generic Glaucoma Drug
• Medicare Change Heralds Easier Device Trial Reimbursements
• Teva MS Drug Patents Invalidated By Fed. Circ.
• Grunenthal Says Actavis, Alkem Infringed Painkiller IP
• Hansen Defendants To Pay $8.5M To Settle Investor Suit
• FDA Sounds Alarm Over J&J Antifungal Drug Nizoral
• Expert In Chinese Law Joins Greenberg Traurig IP Group
• Advanced Bionics Ear Injury Claims Escape Preemption
• EU Finds No Increase In Cancer Risk From Diabetes Drugs
• 7 Cases In Darvocet MDL Sent Back To State Court
• Smith & Nephew, Rival Company Drop Noncompete Suit
• Merck Attacks Watson, Actavis Over Birth Control Patent
• Class Dismissed: Recent Lessons From The Supreme Court
• What A US-China Investment Treaty Would Mean For US Cos.
• Edwards Tells Justices To Skip CoreValve Patent Case
• NECC Insolvency Ruling Will Pave Way For 3rd-Party Suits
• Sens. Introduce Revised Drug Compounding Bill
• S&N Settles $56M Trade Secrets Suit Against Contractors
• Rival Drug Data Co. Hits IMS Health With Antitrust Lawsuit
• GOP Questions Smithfield Deal's Effect On Heparin Supply
• Supplement Co. Can't Dodge False Ads Suit Over Creatine Line
• Medical Co. Denied Immediate Appeal Bid In Worker RICO Row
• Doctor Loses Bid To Block Bausch & Lomb's Slogan Use
• FDA Acknowledges Problems In Approach To Riskiest Drugs
• Fed. Circ. Rejects Bimeda Bovine Anti-Inflammatory Patent
• Mylan Settles With Orion Over Planned Stalevo Generic
• DLA Piper Patent Wiz Joins McGuireWoods' LA Office
• Novartis, Eisai Sue Rivals Over Planned Banzel Generics
• An Expert Out Of Her Element May Cost You
• Novartis Won't Face Punitives In Bone Drug Suit, Judge Says
• GSK's China Misadventures Put Heat On Foreign Drug Trials
• GSK To Pay $229M To Settle US Avandia Suits
• Natco Asks Fed Circ. To Reverse Gilead's Tamiflu Win
• Ropes & Gray To Investigate GSK Bribery Scandal In China
• Cornerstone Sues Exela Over Generic Hypertension Drug
• Drug Buyers Urge Class Cert. In Cephalon Off-Label Use Suit
• FDA Reveals Criteria For Importing Unapproved Drugs
• Deals Rumor Mill: Ally, Blackstone, Yankee Candle
• 500 Days Of The Revised Removal Statutes
• Aspen Dangles £700M Bid For GSK Drugs
• WL Gore Escapes Suit Over Heart Device Patent
• Be Sure To Include Method Claims In A Pharma Product App
• Generics Cos. Haven't Shaken Label Claims Post-Mensing
• Carter Ledyard Adds Patent Atty From Loeb & Loeb
• Medicis Conspired To Block Generic Solodyn, Suit Says
• MLB Won't Balk In Fla. Drug Clinic Case
• FDA Targets 15 Companies Over Bogus Diabetes Treatments
• Omnicare, Fla. Nursing Homes Settle Faulty Billing Suit
• FDA Wants Preemptive Lupus Treatment Suit Nixed
• Stryker Fax Recipients Urge Class Cert. Over TCPA Claims
• FTC Leader Backs Tough Pay-For-Delay Legislation
• And Now A Word From The Panel ...
• Medtronic Can't Duck Injury Suit Over Bone Graft Product
• GSK Claims R&D Misconduct In China Has Been Eliminated
• DC Circ. Affirms Execution Drug Import Ban
• Rainmaker Q&A: Miles & Stockbridge's Michael Brown
• Reilly Pozner Asks To Join GSK Avandia Class Action
• Another Ex-ArthroCare Exec Cops To $400M Fraud Scheme
• Shortcomings Of Best Practices Report On Drug Labeling
• 3rd Circ. Orders GSK To Trial Over Paxil Deal With Mylan
• Mylan Infringed Cephalon Painkiller Patents, Judge Says
• CORRECTED: HHS Sets Final Rule For Orphan Drugs Under 340B Program
• Fed. Circ. Won't Put DuPont On $18M Hook In Enzyme IP Case
• CVS Unfair Competition Claims Go To Arbitration, Judge Says
• ResMed Takes New ITC Action To Enforce Sleep Aid Patents
• Deals Rumor Mill: Dell, Onyx, Telefonica
• Bipartisan Bill Would Unlock User Fees For Drugs, Devices
• FDA Carves Out Broad Powers In Drug Inspections
• Ex-Bristol-Myers Exec To Forfeit Profits From Insider Trades
• EU Clears Baxter's $4B Gambro Buy With Conditions
• Gene Patents Won't Disappear Post-Myriad
• Rainmaker Q&A: Pachulski's Bradford Sandler
• Debating The Ethics Of Children's Organ Transplants
• GSK Says Execs May Have Broken Chinese Bribery Laws
• Teva, Amphastar Protected By Safe Harbor In IP Suit: Judge
• Boehringer Can't Shake Pradaxa Warning Label Claims
• Va. Court Urged To Reverse USPTO Neurological Patent Ruling
• SEC Sets The Bar Low In Suit Against SAC Boss Cohen
• NECC Victims Seek To Sue Others For Meningitis Outbreak
• FDA Reverses Course On Fecal Transplant Requirement
• Now Is The Time To Invest In Saudi Health Care Market
• Judges Warn Drug IP Attys To Dial Back Legal Maneuvers
• ITC Accepts Apex Consent Order, Ends ResMed Patent Probe
• Law360's Global 20 Firms Blaze New Trails Worldwide
• Pfizer Resolves 700 Suits In Chantix Depression MDL
• Marijuana Advocates Ask High Court To Mull Reclassification
• AbbVie Hits Roxane With Patent Suit Over Norvir
• Vivus Inks 11th-Hour Compromise To Avoid Proxy Fight
• Illumina, Complete Genomics Settle Patent Disputes
• DePuy Hits Ex-Sales Reps With Trade Secrets Suit
• DOJ Asked For More Details In Novartis Kickback Suit
• Mallinckrodt Pays $3.5M To Settle Kickback, FCA Claims
• Health Cos. Want Antitrust Cases Consolidated In Kan.
• Illumina Seeks To Overturn $115M Award In Patent Row
• Novartis Challenges Puerto Rican Drug Oversight In High Court
• Ranbaxy Sues First Databank For Trade Libel Over Acne Drug
• Merck To Pay $23M To Settle Vioxx Economic-Loss Claims
• Rainmaker Q&A: Cooley's Michael Rhodes
• The Best Rule Of Reason For Pay-For-Delay
• A Tough Year For Personal Care Products
• Riegel Loophole Keeps PMA Device Cases Afloat, Barely
• Teva Drug Would Infringe Mylan Patent, Judge Says
• Novartis Under Investigation Over MS Drug Marketing
• Pfizer, Takeda Units End Antitrust Case Over Protonix Patent
• Ex-ArthroCare CEO, CFO Indicted For $400M Earnings Fraud
• GSK Finance Exec Blocked From Leaving China, Co. Says
• Warburg Sells Drug Co. Talon In Backloaded $206M Deal
• ResMed, Apex Medical Fight Over Terms Of ITC Sleep Aid Deal
• Medicare Packaged Pay Will Squeeze High-Tech Hospital Care
• Choose Your mHealth Revenue Model Carefully
• Activist Rejects Settlement Offer Ahead Of Vivus Proxy Vote
• SigmaPharm Gets Skelaxin Suit Sent Back To Pa. Court
• FDA Urges Congress To Fix Compounding Oversight Issues
• Report Finds High Costs For Pay-For-Delay Drugs
• Activist Claims Vivus Proxy Vote Delay Cheats Shareholders
• Sandoz, Mylan Slip Teva Patent Suits Over MS Drug Research
• J&J To Pay $23M To Settle Investors' Drug Recall Suit
• Greenberg Traurig Adds Life Sciences Litigator In Atlanta
• K-V Pharma Gets Judge's Nod To Collect Ch. 11 Plan Votes
• 2nd Circ. Orders Schemer To Repay $10M To Morgan Stanley
• Rainmaker Q&A: Greenberg Traurig's Nancy Mitchell
• A Clear Guidance From OIG For Device Manufacturers
• J&J, Endo Pharma Units Face More Pelvic Mesh Claims
• DOJ Wants Ex-SAC Trader's Bid For Privileged Docs Quashed
• Abbott Shells Out $710M To Expand Heart, Eye Portfolio
• 8th Circ. Affirms Pfizer's Dismissal From Drug Injury Suit
• 5 More Countries Approve Pfizer Arthritis Drug Xeljanz
• Vivus Delays Annual Meeting, Blasts Activist Investor
• A Picture Of Health: Medical Tech Private Equity
• Edwards Wants Nerve-Tech Patent Nixed In Medtronic IP Row
• Leahy Wants NIH To Make Myriad License Out Patents
• Everett Hits Rival Acella With Supplement Patent Suit
• 4th Circ. Backs Remand Of W.Va. Zoloft Birth Defect Suits
• GSK Sent Bribes Through Travel Agencies, China Says
• The High Court's Dangerous Reset On Gene Patents
• SEC Probes Aveo Over Failed Renal Cancer Drug
• Bayer To Pay $74M To Settle Cipro Pay-For-Delay Fight
• FDA Details Structure Of Drugmakers' Pediatric Study Plans
• Testing Flaw May Affect Some Intuitive Devices, FDA Says
• GSK Dodges Putative Class Claims Over Avandia Payments
• FDA Warns Against Delaying Inspectors, Details Drug Seizures
• Philips Doles Out Vouchers To Settle AirFloss Suit
• Deals Rumor Mill: Smithfield, Swiss Re, GLG
• 10 Personal Liability Pitfalls For Directors And Officers
• USTR Urges India To Amend Solar, Drug Rules
• Medtronic Valve Sales Blocked In Germany In Edwards IP Row
• Watch The Hot Spots For Pharma Self-Regulation
• Rainmaker Q&A: Paul Hastings' Michael Fitzgerald
• Texas Suit Takes Aim At Johnson & Johnson Pelvic Mesh
• Bellwether Bard Case Ends In Mistrial For Improper Testimony
• FDA Still Under Gun On Antibiotics, Despite Hopeful Signs
• Sunovion Asks Fed. Circ. To Toss Lunesta Ruling
• USPTO Validates Bard Blood Vessel Patent In Blow To Gore
• Swanson Martin & Bell Beefs Up Product Liability Group
• UCB Launches Legion Of Suits To Protect Epilepsy Drug IP
• Myriad Sues Again To Block Rival Gene-Based Cancer Test
• Arthrex Can't Dodge KFx Patent Suit Over Suture IP
• FTC Seeks More Info On $8.5B Actavis-Warner Chilcott Merger
• GSK Execs Copped To Bribery, Tax Crimes, China Says
• Judicial Gatekeeping Suffers A Setback
• Pharmacy Compound Infringes Horse Drug Patents, Suit Says
• Stem Cell Patent Case Will Be Early Test Of Myriad's Reach
• Medical Device Cos. See Opening For Killing ACA's $30B Tax
• Holland & Knight Picks Up Ex-White Collar Prosecutor
• Hospitals Fire Back In Defense Of 340B Drug Discounts
• UK Regulator Blocks Wockhardt European Drug Sales
• Feds Order Farm To Stop Selling Antibiotic-Tainted Cattle
• 9th Circ.'s Rare Gift Of Time To Remove Case
• Myriad Sues Ambry Over Supreme Court-Backed Patents
• FDA Softens 'Dear Doctor' Letter Guidance For Drugmakers
• Goodwin Procter Snags Ex-Kirkland Life Sciences, IP Pro
• Synthes Bone Repair Patent Invalid, Fed. Circ. Rules
• Pain Now Or Later? Thermo Fisher Tastes Earnout Bitters
• India Panel Delays Vote On $1.6B Mylan, Agila Merger
• GOP Leaders Want Answers On ACA Employer Mandate Delay
• Support For Drug E-Labeling Mixed, GAO Says
• FDA's Generic-Drug Plan Will Live Or Die On Sameness Rule
• 7th Circ. Junks Overbilling Claims Against Walgreen, Par
• Pharmstandard To Spin Off OTC Unit, Buy Singaporean Co.
• Envision Pharmaceutical Announces Sale To TPG
• Silver Point Seeks Full Interest Payment In K-V Bankruptcy
• Bingham Adds Ex-DLA Piper IP, Litigation Pro In Tokyo
• FDA Gives Device Makers Few Ways Out Of Reporting Injuries
• Lance Armstrong, FRS Look To Sink Supplement Class Action
• Novartis Whistleblower Wants State FCA Claims Revived
• Myriad Illuminates High Court's Approach To Section 101
• HHS Floats Proposal To Upend Generic-Drug Labeling Regs
• GSK Sales Director Claims He Was Fired For Being A Man
• Teva's $1.6B Pfizer Patent Deal Isn't Covered, Insurer Says
• FDA Details Risk Reduction In Biologic Clinical Trials
• Thermo Fisher In $4M Suit For Alleged Post-Merger Scam
• Bayer Inks Deal With Cipro Buyers In Pay-For-Delay Suit
• Unigene Claims $64.2M Liabilities In Ch. 7 Petition
• Roche Defeats Class Cert. Bid In Canadian Accutane Action
• Purdue Sues Teva To Block 'Abuse-Proof' OxyContin Generic
• Baxano To Pay $6M To Settle FCA, Kickback Allegations
• Ex-Olympus Execs Get Suspended Sentences In Fraud Case
• Philips Hit With Class Action Over Unused Vacation Time
• Novartis Sues Accord Over Kidney Transplant Drug Patents
• Shipping Drugs To Ga. Just Got More Complicated
• Alpex Aims To Block Zydus' Generic Obesity Drug
• Generics Makers Escape NJ Accutane Mass Tort
• Fosamax Ruling Puts Preemption In Play For Branded Drugs
• Consumers Urge Fed. Circ. To Strike Down Stem Cell Patent
• Scope Of Statutory Research Exemption Remains Unresolved
• FTC V. Actavis: Reconciling Conflicts In Rule Of Reason
• BMS, Sanofi Pushed Docs To Overprescribe Plavix, Suit Says
• Par, Alkermes Sue Breckenridge To Block Generic Megace
• EU Adds Pharmaceuticals To Water Pollution Watch List
• Roche Pays $220 Million For Blood Testing Innovator
• Baxter Offers EU Antitrust Fixes On $4B Gambro Buy
• Weil Reps Avista Capital Fund In Dental Implant Deal
• Re-Exam Nixes Baxter's $23M Patent Win, Fed. Circ. Rules
• Medical Equipment Competitive Bids Start Despite Protests
• Lupin Hit With Suit Over Generic Prezista
• FDA Again Aims To Keep Misconduct Probes Secret
• Deals Rumor Mill: Carlyle, Providence Equity, Toksoz
• A Primer On WTO Dispute Settlement
• Chinese Police Detain GlaxoSmithKline Employees In Probe
• 11th Circ. Says Patent Claims Aren't Just For Fed. Circ.
• Morrison Dooms Part Of SAC Insider Case, Ex-Trader Says
• Merck Can't Duck Jury Award In Fosamax Bellwether Suit
• USPTO Defends Patent Term Adjustment Math To Fed. Circ.
• Davis Wright Flouted Ethics Rules In Coverage Row: Omeros
• FDA Details Steps For Streamlined Antibiotic Approval
• King & Spalding Adds Life Sciences, Health Expert In DC
• 9th Circ. ERISA Ruling Spurs Meritless Suits, Chamber Says
• Pfizer Files More Suits To Block Generic Toviaz
• AstraZeneca Sues Mylan Over Planned Vimovo Generic
• $10B Amgen Bid Snubbed By Onyx Pharmaceuticals
• Deals Rumor Mill: KKR, Blackstone, BC Partners
• Isolating The DNA Of Patent Damages
• Beware Of Malware: FDA On Cybersecurity Risks